L&L Bio Participates in J.P. Morgan Healthcare Conference 2026 Annual Conference (1/12/2026)
Phase II/III Clinical Study of (LB1410 + Lenvatinib) +/- LB4330 in Immunotherapy-Resistant Cervical Cancer lauched in China, First Patient Dosed (10/17/2025)
L&L Bio Shortlisted for the Team Final of the China Innovation and Entrepreneurship Competition (7/31/2025)
L&L Bio Participates in SAPA 2025 Annual Conference (9/27/2025)
Series B++ Financing Fuels Phase II/III Cervical Cancer Trials(12/2/2025)